Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 48

Results For "program"

1968 News Found

ISVIR 2026 showcases cutting-edge interventional radiology in India
News | January 14, 2026

ISVIR 2026 showcases cutting-edge interventional radiology in India

Sabitha highlighted the growing relevance of minimally invasive therapies in modern medicine


Avista Therapeutics unveils AI-powered expansion of gene therapy platform
R&D | January 14, 2026

Avista Therapeutics unveils AI-powered expansion of gene therapy platform

The company is rolling out ARTEMIS, a next-generation AI platform for capsid design


Camurus’ Oclaiz NDA resubmission accepted by FDA
Drug Approval | January 14, 2026

Camurus’ Oclaiz NDA resubmission accepted by FDA

The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of June 10, 2026


GRIN Therapeutics launches global Phase 3 trial for groundbreaking GRIN-NDD therapy
Clinical Trials | January 14, 2026

GRIN Therapeutics launches global Phase 3 trial for groundbreaking GRIN-NDD therapy

GRIN-NDD is one of the most complex neurodevelopmental disorders with limited treatment options today


Zealand Pharma taps Denmark’s supercomputer to supercharge drug discovery
R&D | January 14, 2026

Zealand Pharma taps Denmark’s supercomputer to supercharge drug discovery

Gefion, powered entirely by renewable energy, boasts more than 1,500 NVIDIA GPUs


AbbVie strikes deal with Trump administration on drug prices, US investment
News | January 13, 2026

AbbVie strikes deal with Trump administration on drug prices, US investment

AbbVie will offer reduced prices for its medicines in Medicaid and commit $100 billion over the next decade to US research, development and capital investments, including domestic manufacturing


Teva and Royalty Pharma partner in $500 million deal to fast-track vitiligo treatment
Clinical Trials | January 12, 2026

Teva and Royalty Pharma partner in $500 million deal to fast-track vitiligo treatment

Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding